

Novago Announces First Patient Dosed with NG004 in Phase 1b Trial for Potential Treatment of Acute Spinal Cord Injury

Zurich, Switzerland (7.1.2025).

NovaGo Therapeutics AG, a clinical stage biotech company focused on advancing therapeutics for patients with spinal cord injury or diabetic retinopathy, today announced the Initiation of NG004 Phase 1b trial for treatment of acute spinal cord injury. Based on Neurimmune's RTM technology™, NG004 is a fully human antibody with improved efficacy and biophysical properties.

The SPROUT phase 1b study will evaluate the safety and pharmacology of an anti-Nogo-A antibody in up to 21 acute spinal cord injury patients in a multicenter and multi country clinical trial. 4 centers in Germany and 2 in Switzerland are actively recruiting, to learn more please visit: EUCT ([2024-514303-34-00](#))

The anti-Nogo-A antibody NG004 blocks and neutralizes the Nogo-A protein. Studies in animals have shown that the Nogo-A protein stops damaged nerve fibers in the spinal cord from growing back after an injury. This antibody helps to block these effects, allowing the nerves to heal and aiding spinal cord recovery.

"This milestone marks Novago's transition to a clinical stage company with its first asset. We are thrilled to start the clinical development of NG004 for acute spinal cord injury." said Stefan Moese, CEO of Novago. "Seeing NG004 transition to clinical trials is a significant achievement offering a much-needed, first-in-class treatment for patients with acute spinal cord injury." Martin Schwab, CSO of Novago.

About NovaGo Therapeutics

Founded in 2015, NovaGo Therapeutics is a clinical stage biotech company focused on the development of human antibody therapeutics targeting blood vessel and nerve regeneration. A spin-off company from the University of Zurich, leveraging Neurimmune's Reverse Translational Medicine™ technology, NovaGo has several next generation antibody therapeutics in development for CNS and Ophthalmology indications.

Contact for Media

Please contact us via: media@novagotx.com